Retina Implant AG and Okuvision to Present Patient Perspectives and Clinical Data at the Retina International World Congress 2016

TAIPEI, Taiwan, July 9, 2016 /PRNewswire/ --

Retina Implant will be presenting the scientific rationale as well as having a patient offering their perspective of the device in practice.  

Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), announced today that they will be presenting new data, and having a patient with the company's CE-marked Alpha AMS^® device discussing his experience of living with the subretinal implant, at the Retina International World Congress (RIWC) 2016 on 9-10 July in Taipei, Taiwan.

The parallel session, entitled "Updates on Retina Implant Alpha", will be held in room 101A and 101B on Saturday 9 July and moderated by Prof. Caroline Chee, Head of Surgical Retina at the National University Hospital, Singapore. It includes:

• "Scientific Rationale of Retina Implant," presented by Prof. Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tübingen, Germany and founder of Retina Implant AG. Prof. Zrenner's presentation will take place from 16.00-16.30 p.m.
• "Implantation of Retina Implant Alpha," presented by PD Dr. Sachs, Retina Implant's senior consultant and head of the Department of Ophthalmology, Clinic Dresden-Friedrichstadt, Germany. The presentation will be between 16.30-17.00 p.m.
• "My witness: Living with Retina Implant Alpha," is a patient presentation led by Mr. Peter Böhm, who will be discussing his personal experience with the implant. This will be presented from 17.00-17.30 p.m.

The Alpha AMS subretinal implant (CE-marked March 2016) is the next generation of the Alpha IMS (CE marked in 2013).

Okuvision will also be presenting at the congress. Their session, held on 10 July in room 101A and 101B, is entitled "Transcorneal Electrical Stimulation OKUVISION". The session will be moderated by Reinhard Rubow, CEO of Okuvision and Board Member of Retina Implant, and includes:

• "Scientific Rationale of Transcorneal Electrical Stimulation (TES)," presented by Prof. Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tübingen, Germany and founder of Retina Implant AG. The presentation will take place between 09.00-09.30 a.m.
• "Installation and operation of TES," will be presented by Dr. Guido Blaess, Product Manager for Okuvision GmbH. Dr Guido's presentation will run from 09.30-10.00 a.m.
• "Results of Clinical Trials," is also to be presented by Prof. Zrenner between 10.00-10.30 a.m.

The OkuStim^® device delivers individually adjusted levels of TES under physician guidance, with the goal of slowing the progression of RP-related blindness. Both companies are silver sponsors of the congress.